Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Sees Large Drop in Short Interest

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the target of a significant decline in short interest in the month of April. As of April 15th, there was short interest totaling 16 shares, a decline of 99.9% from the March 31st total of 15,516 shares. Based on an average daily trading volume, of 356,323 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the shares of the company are sold short.

Oncotelic Therapeutics Stock Performance

OTCMKTS:OTLC traded up $0.00 during midday trading on Friday, hitting $0.04. The company’s stock had a trading volume of 342,935 shares, compared to its average volume of 210,132. Oncotelic Therapeutics has a fifty-two week low of $0.02 and a fifty-two week high of $0.11. The firm’s 50 day moving average is $0.04 and its 200-day moving average is $0.07. The company has a debt-to-equity ratio of 0.01, a current ratio of 0.07 and a quick ratio of 0.07. The firm has a market cap of $16.75 million, a P/E ratio of 0.06 and a beta of -0.59.

Oncotelic Therapeutics (OTCMKTS:OTLC) last issued its quarterly earnings data on Wednesday, April 15th. The company reported $0.59 EPS for the quarter.

About Oncotelic Therapeutics

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.